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Abstract
Background: The nucleoside analogue arabinosylcytosine (araC) has been used for many years in
the treatment of acute leukemia. Evidence in the literature suggests that araC may inhibit the
growth of human colon carcinoma cell lines as well. Because araC action interferes with normal
nucleoside metabolism, it is highly toxic to a number of normal cell types including bone marrow
and intestinal mucosa cells. Here we investigate whether the omega-3 fatty acid docosahexaenoic
acid (DHA) could selectively target araC toxicity toward colonic tumor cells while protecting the
normal cells in vitro.
Results: Cultures of normal rat colonic epithelial cells (4D/WT) and those transformed by v-src
(D/v-src) were supplemented with graded concentrations of DHA or arachidonic acid (AA) alone
or in combination with araC. AraC was only 1.6 fold more toxic to D/v-src than 4D/WT in cultures
without added fatty acids. Supplementing with as little as 3 µM of either AA or DHA increased araC
toxicity by more than 30-fold in the tumorigenic cells. The toxic effect of araC on the normal cells
was also increased by the fatty acid supplementation. IC50 values were decreased 1.7 fold by DHA
in the 4D/WT cells but a more than 7-fold decrease was observed during AA supplementation. As
a result, the therapeutic index of araC (IC50 normal/IC50 tumor) was more than 3-fold higher in the
DHA than the AA supplemented cells. The expression of protein kinase C isoform epsilon was
decreased in AA alone supplemented D/v-src cultures but in combination with araC decreased only
in DHA supplemented 4D/WT cells.
Conclusion: Low dose DHA supplementation may enhance araC chemotherapy in colon cancer
while protecting normal tissues, possibly through control of PKC signalling pathways.
Background
Colorectal cancer is the second most common cause of
death among men and women in North America [1]. This
disease may evolve from genetic alterations in protoonco-
genes or tumor suppressor genes. There has also been evi-
dence indicating dietary factors, such as fat and fiber,
affect several stages of colon carcinogenesis. Japanese have
a lower incidence of colon cancer as compared to North
Americans, which could be partially attributed to higher
amounts of n-3 fatty acids and low amounts of saturated,
monounsaturated and n-6 fatty acids in their diets [2].
Arabinosylcytosine (araC) has been used for many years
in the treatment of acute leukemia. Some later studies
have suggested that araC and the related drug gemcitabine
may be useful in inhibiting the growth of human colon
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with normal nucleoside metabolism, a number of normal
cell types particularly dependent on salvage of nucleo-
sides, are extremely sensitive to araC; these include the
bone marrow and intestinal mucosa. In patients with
leukemias and non-Hodgkins lymphoma treated with
araC, gastrointestinal and hematopoietic toxicities pre-
dominate and frequently limit dose escalation [4].
We have previously demonstrated that docosahexaenoic
acid (DHA) can enhance araC and doxorubicin toxicity in
leukemia cells and araC toxicity in transformed rat fibrob-
lasts in vitro [5,6]. More recently, we showed that at least
part of this differentially selectivity was due to effects of
DHA on two metabolic enzymes cytidine kinase and cyti-
dine deaminase [7]. In vivo we showed that DHA had ben-
eficial effects on both the bone marrow compartment and
gastrointestinal tract of tumor-bearing, araC treated rats
[8]. We also demonstrated that a low dose of dietary DHA
supplementation could prolong the life span and limit the
occurrence of toxicity in L1210 leukemic mice [9]. The
current study was designed to investigate whether low
dose DHA could selectively target araC toxicity toward rat
colon tumor cells in vitro.
Studies show that araC engages in an array of signaling
events including activation of protein kinase C (PKC)
[10]. Essential fatty acids of the omega-3 and omega-6
series are also known to have effects on cell membrane
signaling which includes PKC [11,12]. Because both araC
and DHA could potentially modulate cell death and drug
toxicity in overlapping pathways, we also examined the
expression of various PKC isoforms during fatty acid sup-
plementation and drug treatment.
Results
Using the sulforhodamine dye binding assay the IC50 val-
ues for arachidonic acid (AA), DHA, and araC were exam-
ined in the normal colonic epithelial cell line 4D/WT and
in the v-src transformed variant, D/v-src (Table 1.). AA
and DHA had approximately the same toxicity profile in
both cell types and showed 5-7-fold higher toxicity in the
tumorigenic versus the normal epithelial cells. The IC50
value for araC in 4D/WT was 67 µM and only slightly
lower in the D/v-src cells at 42 µM. Pre-incubating 4D/WT
cells with 3 µM DHA (well below the IC50 values for either
cell type) only slightly increased araC toxicity (1.7-fold)
while pre-incubation with 3 µM AA increased araC toxic-
ity 7-fold in the normal 4D/WT cells. Pre-incubation of
the tumorigenic cell line, D/v-src with either 3 µM DHA or
AA resulted in a dramatic 40-fold increase in araC toxicity.
Therefore the improvement in therapeutic index is 30-fold
in the presence of 3 µM DHA (p < 0.03). Toxicity of other
fatty acids (saturated, unsaturated, series n-9, n-6 and n-3)
either alone or in combination with araC were not differ-
ent between normal and tumor cells in culture (data not
shown).
The survival curves in araC treated cultures with or with-
out fatty acid supplementation are shown in Figure 1. The
survival rates were not different between the normal and
the transformed cells at very low araC concentrations (0.1
and 0.2 µM). At 0.4 µM araC the surviving fraction of nor-
mal cells is statistically higher for 4D/WT cells in either
DHA or AA supplemented media (> 97%) compared to D/
v-src cells (<60%). At about 6 µM araC there is no thera-
peutic benefit of AA treatment given that the level of kill is
equivalent between 4D/WT and D/v-src cells at this point
in the dose response curve. However, in DHA-treated 4D/
WT cells, the survival curves were statistically higher than
D/v-src cells at all araC concentrations and never dropped
below 50% over the range of concentrations used in this
experiment.
The effect of araC on the morphology of 4D/WT and D/v-
src cells treated with or without DHA or AA is shown in
Figure 2. AraC at 10 µM, killed only a few 4D/WT cells
growing in 10% FBS containing medium (panel A). More
4D/WT cells were killed when cultures were supple-
mented with DHA (panel C), however less than half of the
cells survived when AA replaced DHA in the araC treated
cultures (panel B). In contrast, 2 µM araC caused potent
Table 1: Toxicity of fatty acids or araC alone and in combination on normal (4D/WT) and transformed (D/v-src) rat colonic epithelial 
cells1
DHA (n = 3) AA (n = 3) AraC (n = 3) AA-araC (n = 3) DHA-araC (n = 4)
IC50 µM
4D/WT cells 87.8 ± 10.2 91.1 ± 18.4 67.4 ± 11.1 9.3 ± 1.4 39.1 ± 10.4
D/v-src cells 14.9 ± 5.9* 12.2 ± 5.0* 41.8 ± 2.8 1.0 ± 0.6 1.3 ± 0.5*
1For the drug and fatty acid toxicity assays, cells were cultured in media supplemented with graded concentrations of araC or the fatty acids for 24 
hrs. For the fatty acid supplemented drug toxicity assays, cells were treated with 3 µM DHA or AA for 24 hrs. Cells were then cultured in media 
supplemented with DHA or AA and graded concentrations of araC for an additional 24 hrs. Values are means ± SEM with sample sizes indicated in 
parenthesis. Values followed by * are significantly different from the values within the same column (p < 0.05).Page 2 of 8
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(panel E) or DHA (panel F) compared to araC only treated
cultures (panel D).
The expression of the PKC isozymes α, δ, ε and ζ in 4D/
Wt and D/v-src cells treated with or without araC or the
fatty acids or a combination of the fatty acids and araC are
shown in Figure 3. PKC δ expression was higher in normal
colonic epithelial cells than in the transformed variant.
Treatment with araC decreased PKC δ expression in the D/
v-src cells in both FBS only and DHA/AA supplemented
conditions. Less PKC ε was detected in the AA supple-
mented D/v-src compared to all other treatments. Densit-
ometry and statistical analysis revealed an interaction
between araC and fatty acid treatment in both the 4D/WT
and D/v-src cells. In the expression patterns of PKC iso-
forms ε and ζ, the expression of both PKC isoforms was
decreased by araC only when DHA was supplemented.
There was no statistically significant change in PKC α
expression under any treatment conditions.
Discussion
There is considerable evidence that nutrition and lifestyle
factors have major impact on the early stages of
Survival curves for cells cultured in media supplemented with DHA or AA and treated with graded concentrations of araCFigure 1
Survival curves for cells cultured in media supplemented with DHA or AA and treated with graded concentrations of araC. 
4D/WT and D/v-src cells were cultured in media supplemented with 3 µM DHA or AA for 24 h. Fresh media was added to 
include both fatty acids and graded levels of araC for an additional 24 h. Cell viability was determined by the SRB dye binding 
assay by comparing to control cells not treated with fatty acid or araC. Values are means ± SEM of 3 – 4 separate experiments. 
Significant differences were detected between tumor and normal cells at all concentrations of drug tested up to 10 µM araC, 
beyond which only normal cells co-supplemented with DHA grew significantly better than all other cell cultures. DHA and AA 
supplemented tumor cell cultures were not statistically different from each other at any araC concentration tested. DHA and 
AA supplemented normal cells were not significantly different at 0.1, 0.2 and 3 µM araC. AraC was significantly more toxic to 
the AA supplemented normal cells compared to DHA supplemented normal cells at all other concentrations of drug.Page 3 of 8
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The effect of araC on the morphology of 4D/WT and D/v-src cells treated with or without 3 µM AA or DHA. 4D/WT cells 
(A, B, C) or D/v-src cells (D, E, F) were cultured in medium supplemented with 3 µM AA (B, E) or DHA (C, F) or a medium 
without the fatty acid supplementation (A, D) for 24 h. Cells were then treated with either 10 µM (4D/WT cells, A, B, C) or 
2 µM (D/v-src cells, D, E, F) araC for an additional 24 h. Dead cells are indicated by the arrow signs. All photographs are at 
200× magnification.Page 4 of 8
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PKC isoform expression as determined by Western blot. 4D/WT and D/v-src cells were cultured in media supplemented with 
3 µM DHA or AA for 24 h. Fresh media with/without the fatty acids and 10µM araC was added. Cell lysates containing 30 µg 
protein/lane were loaded and separated on 10% SDS-PAGE gels. Gels were transferred and probed as described in the Materi-
als and Methods. Densitometric values are means ± SEM of 3 – 4 separated experiments. Bars with different letters within the 
same PKC isoform and cell type are significantly different (Fisher's protected LSD test).Page 5 of 8
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clear is the role, if any, for nutritional supplementation as
part of an adjuvant therapeutic strategy in colon cancer
treatment. Given that colon cancer is particularly resistant
to existing chemotherapeutic drugs, and at best an
increase of 20% in five-year survival rate is achieved with
combination 5-fluorouracil (5-FU) and levamisole/leu-
covorin, improvements in drug toxicity/selectivity would
certainly be helpful.
Nucleoside chemotherapeutic drugs including araC, gem-
citabine and 5-FU all have intracellular targets and
interfere with the metabolism of normal nucleosides to
disrupt cellular growth. Tissues with high turnover rates
such as bone marrow and intestinal mucosa are particular
sensitive to those drugs. The present study demonstrated
that low dose DHA substantially enhanced araC's ability
to kill tumorigenic colonic epithelial cells while only mar-
ginally increasing toxicity toward the normal mucosal cell
line. While AA also had sensitizing activity, it was much
less selective than was DHA. While the concentration of
DHA in normal FBS, or in the blood of individuals con-
suming habitual North American diets is very low, we and
others have shown that levels as high as 100 µM can be
achieved in blood plasma through dietary supplementa-
tion of mouse diets [9]. In several in vitro and in vivo sys-
tems we, and others, have demonstrated that long chain
polyunsaturated fatty acids, particularly those found in
fish oils, can enhance tumor kill by chemotherapeutic
drugs and protect normal tissues [5,8,13]. In leukemia
treatment, where araC is often used in combination ther-
apy, the plasma levels reach up to 2 µM during high dose
or low dose infusions. The observation here, that distinct
differences in toxicity were observed between 0.1 and 1
µM, supports the idea that DHA will improve the clinical
efficacy of araC at therapeutically relevant doses.
Enterocytes and colonocytes express many PKC isoforms
including α, βI, βII, δ, ε, η, θ, ζ, and ι. most of which are
activated in the post-mitotic compartment. Colon tumors
from both humans and rats tend to show decreased abun-
dance of α, βI, δ, ε, ζ and/or η. Perlletti and co-workers
have demonstrated a lower PKC δ expression in rat
colonic epithelial cells [14]. Consistent with those previ-
ous reports, we showed significantly lower expression of
PKC δ in D/v-src cells as compared to 4D/WT cells. Over-
expression of δ in CaCo-2 human colon tumor cells has
been shown to decreased growth [15] and at least partially
reverses the malignant phenotype of src transformed rat
colonic epithelial cells [14]. PKC is an important modula-
tor of araC toxicity [10,16] and a global reduction in PKC
expression correlates with increased araC cytotoxicity
[16]. Our study showed a potent down-regulation of PKC
δ with araC treatment in tumor (CLD/src) but not in nor-
mal cells (CLD/WT), which may be related to the higher
cytotoxity of araC to the transformed cells, in accordance
with the previous report.
Chapkin's group has shown that dietary fat type can mod-
ulate PKC isozyme expression patterns in the colon [17].
A recent study by Mirnikjoo [18] showed that EPA and
DHA, but not AA, were active inhibitors of the catalytic
domains of several kinases including PKC. Nair and cow-
orkers [19] showed similar selectivity of n-3 fatty acids to
modulate PKC activity and subcellular redistribution in
cardiac myocytes. In the present study, PKC ζ expression
was decreased by the presence of DHA but not by AA in
the normal colon cells with or without araC treatment,
suggesting DHA can modify the PKC expression in normal
cells. However, our results didn't show a significant effect
of DHA on the levels of this PKC isozyme expressed in the
transformed cells, suggesting an interaction between the
cell type and the effect of DHA on PKC expression. PKC ε
content was also influenced by the fatty acids and drug in
a complicated way. The decreased expression of ε in the
D/v-src cells in the presence of AA was not observed when
cells were co-treated with araC. In the 4D/WT cells, on the
other hand, AA and DHA alone had no effect on PKCε
expression but the DHA-araC combination did down reg-
ulate this isozyme. If one looks for correlations between
the toxicity profiles and PKC expression profiles, an abil-
ity to down regulate PKCε expression in 4D/WT is corre-
lated with lower toxicity of araC. An obvious question is
how this might be achieved at a molecular level, particu-
larly since individually DHA and araC had no effect on
expression, and AA had no combinatorial effect. Though
there does not appear to be a single dominant effect of
one PKC isoform over another, it could be the combina-
tion pattern of expression of the various PKCs that is crit-
ical in determining the final response. For example, the
high expression of PKC ε and low expression of PKC δ in
D/v-src may be a marker of susceptibility. Further experi-
ments are required to determine the molecular nature of
these interacting signalling pathways.
Conclusion
In summary, the present study demonstrated that low
dose DHA or AA supplementation synergistically interacts
with araC to achieve therapeutic gain against the colon
tumor cells. Because DHA, but not AA showed tumor cell
selectivity, this suggests that dietary supplementation pro-
tocols including DHA with araC, gemcitabine or other




The cell lines used in the present research were a generous
gift from Dr. Susan E. Pories, New England Deaconess
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plasma-negative rat colonic epithelial cell lines and the
immortalized nontumorigenic cell line referred to as FRC
TEX CL 4D (referred throughout the text as 4D/WT) and
the derivative transformed cell line FRC TEX CL D/v-src
(referred to as D/v-src), established by transfection of a v-
src sequence into the 4D/WT parental line. D/v-src cells
exhibit the neoplastic phenotype while 4D/WT do not dis-
play anchorage independent growth or form tumors in
vivo. 4D/WT and D/v-src cells were cultured in Dulbecco's
modified Eagle's medium with 10% fetal bovine serum
(FBS), hydrocortisone (0.02 ug/mL), insulin (0.25 ug/
mL), transferrin (0.12 ug/mL), polybrene (1 ug/mL) and
penicillin-streptomycin (50 U/mL) in a humidified envi-
ronment at 37°C in the presence of 10% CO2.
Toxicity assays
IC50 values were determined for 4D/WT and D/v-src cells
treated with or without DHA or AA or a combination of
araC and the fatty acids by protein binding dye
sulphorhodamine B (SRB) assay as we have previously
described (5,6). DHA or AA as the free fatty acids were first
bound to albumin in serum for 1 h at 37°C before dilut-
ing into culture media at 0–500 :M. For the drug (0–1
mM) or fatty acid toxicity assays, approximately 1000
cells/well were plated in 96-well plates and cultured for
24–48 h. Cells were allowed to adhere for a minimum of
6 h before the fatty acid or drug was added.
PKC protein expression
Sub-confluent monolayers of 4D/WT and D/v-src cells
were grown in media supplemented with or without 3 µM
DHA or AA in 100mm plates for 24 h. Media was then
replaced with fresh media ± fatty acid, and/or ± 10 µM
araC and cultured for an additional 24 h. Cells were
harvested, washed three times in cold phosphate buffer
saline (PBS) and resuspended in a small volume of PBS
containing protease inhibitor cocktail (Boehringer Man-
nheim). Samples were sonicated, 10 µL of lysate recovered
for protein assay (Bio-Rad Laboratories, Inc., Hercules,
CA), and an equal volume of 2× hot Laemmli sample
buffer was added. Proteins (30 µg/well) were separated by
SDS-PAGE on 10% acrylamide gels and transferred to
nitrocellulose membrane on a semidry transfer apparatus.
Membranes were blocked in 5% milk powder in Tris-buff-
ered saline (TBS) and probed with the respective primary
monoclonal antibody (Transduction Laboratories,
Lexington, KY) at concentration range from 1:500 to
1:1500 dilution in 1% BSA. Membranes were washed and
then probed with secondary antibodies conjugated to
horseradish peroxidase diluted in 5% milk. Blots were
developed using the enhanced chemiluminescence
method (Amersham) and density of bands quantified by
an imaging densitometer using Northern Eclipse software
(Empix Imaging Inc, Missisaga, ON).
Statistical analysis
Analysis was performed using SPSS general linear model
program version 7.5 (SPSS Inc. Chicago, IL). The effect of
treatment was determined by one-way ANOVA and
Fisher's protected LSD post-hoc test with significance
determined to be p < 0.05. For the cell viability analysis,
data were log transformed to obtain a normal distribution
and plotted and IC50 values determined using a CurveFit
computer software.
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